Mr. John Hennessy:

The issue of transparency was central to the committee report in February 2018. We have been attempting to address it in several ways. I believe we have made progress but if there is more to be done we would be happy to engage with members on how we can strengthen the transparency factor.

I wish to remind members that the National Centre for Pharmacoeconomics reports are published on the website once they are concluded. The deliberations of the drugs group are notified to the particular companies involved. There can be commercial sensitivities around what goes into the public domain. However, we are particularly keen to be as transparent as possible and to report publicly the outcome of the drugs group deliberations.